首页> 外文OA文献 >L-Leucyl-L-Leucine Methyl Ester (LLME) Treated Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Hematological Malignancies

【2h】

L-Leucyl-L-Leucine Methyl Ester (LLME) Treated Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Hematological Malignancies

机译：L-亮氨酰-L-亮氨酸甲基酯（LLME）治疗血液系统恶性肿瘤的非清髓性异基因造血干细胞移植（HSCT）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Wagner J.L.; Grosso D.A.; Brunner J.; Carabasi M.A.; Filicko-OHara J.E.; Mookerjee B.; Flomenberg N.;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Allogeneic Genetically Modified T Cells (HSV-TK) As Adjunctive Treatment in Haploidentical Hematopoietic Stem-Cell Transplantation (haplo-HSCT) of Adult Patients with High-Risk Hematological Malignancies: A Pair-Matched Analysis from the Acute Leukemia Working Party of EBMT [J] . Mohty Mohamad, Labopin Myriam, Velardi Andrea, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：同种异体遗传修饰的T细胞（HSV-TK）作为高风险血液恶性肿瘤的成年患者寄生造血干细胞移植（HAPLO-HSCT）中的辅助治疗：EBMT急性白血病工作组的对分析
2. Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades [J] . Jason P. Cooper, Barry E. Storer, Noa Granot, Haematologica . 2021,第6期

机译：对血液学恶性肿瘤患者的非霉菌调理的同种异体造血细胞移植：两十年来改善了结果
3. Non-myeloablative allogeneic hematopoietic transplantation for patients with hematologic malignancies: 9-year single-centre experience [J] . A. Kew, D. White, K. Thompson, Current oncology . 2014,第3期

机译：非清髓性异基因造血移植治疗血液系统恶性肿瘤：9年单中心经验
4. Intravenous Busulfan Reduces Toxicity Associated with Myeloablative Allogeneic Hematopoietic Transplantation in Patients with Myeloid Malignancies [C] . A. Shimoni, B. Bxelorai, I. Hardan, European Haematology Association . 2002

机译：静脉内的伯鲁兰减少骨髓恶性肿瘤患者患有髓鞘异产造血移植的毒性
5. The burden of parainfluenza virus infection in patients with hematological malignancy and hematopoietic stem cell transplant (HSCT) recipients in the absence of active immunization and approved therapy: The role of infection control. [D] . Hanmod, Santosh S. 2009

机译：在没有积极免疫和批准治疗的情况下，血液恶性肿瘤和造血干细胞移植（HSCT）患者的副流感病毒感染负担：感染控制的作用。
6. Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades [O] . Jason P. Cooper, Barry E. Storer, Noa Granot, 2021

机译：对血液学恶性肿瘤患者的非霉菌调理的同种异体造血细胞移植：两十年来改善了结果
7. Non-Myeloablative (NMA) Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients with Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation (Bu/Flu/TBI) Conditioining: Results of a Phase II Trial [O] . Brammer Jonathan E., Stentz Alex, Dibb James, 2014

机译：非清髓性（NMA）同种异体造血干细胞移植治疗使用白消安，氟达拉滨和全身照射（Bu / Flu / TBI）进行的恶性血液病患者的治疗：II期试验的结果

L-Leucyl-L-Leucine Methyl Ester (LLME) Treated Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Hematological Malignancies

著录项

相似文献

相关主题

期刊订阅